Xcout IntelFreenome
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Subscribe to see Freenome’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Freenome at a glance
Freenome is a biotech company headquartered in Brisbane, United States. It is publicly listed (FRNM) with a market capitalisation of $130.6M. Xcout tracks 18 named people at Freenome, including Aaron Elliott (CEO & Director). Xcout recorded 43 job postings from Freenome in the last 90 days, naming tools such as PyTorch, TensorFlow, MLflow.
Freenome leadership
- Aaron ElliottCEO & Director
- Joseph EdelmanChief Executive Officer & Portfolio Manager
- Linh H. LeChief Financial Officer
- Cheng-Ho LinChief Scientific Officer
- Adam StoneChief Investment Officer
- Julie Tran MSHRChief People Officer
12 more named people on record for Freenome, with roles, board committees and tenure — see the full roster →
Freenome funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $65M | 8 named | |
| Seed | $5.5M | 4 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Freenome
Xcout recorded 43 job postings from Freenome in the last 90 days, from a hiring record Xcout has kept since July 2026.
Tools named in Freenome's job postings
The weekly hiring trend, the roles and locations behind it — see Freenome's hiring signals →
Recent Freenome news
- IPOIPO registration (S-1)
- AcquisitionM&A communication (425)
3 corporate events on record, with sources — see the full timeline →
Hiring vs the trend
Based on 21 job postings in the last 8 weeks (24 Aug – 18 Oct 2026), compared with 181 scale-up healthcare companies.
This describes a hiring pattern — how often Freenome’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Investors
Tech stack
Freenome competitors
A few of Freenome's closest competitors — see the full list of competitors and alternatives →
GRAIL, Inc. is an innovative commercial-stage healthcare and life sciences company headquartered in Menlo Park, California, focused on early cancer detection technologies. The company was acquired by Illumina in 2021.
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
Adela, Inc. is an epigenomics-focused biotechnology company headquartered in Foster City, California. The company is advancing breakthrough approaches for the early detection of multiple types of cancer through blood tests.
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
SAGA Diagnostics provides ultra-sensitive, blood-based molecular residual disease (MRD) detection and monitoring tests for cancer patients. The company's flagship platform, Pathlight, uses tumor whole-genome sequencing and personalized digital PCR assays to detect circulating tumor DNA, primarily serving clinicians and biopharmaceutical partners for early cancer detection and treatment tracking.
Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions and liquid biopsy cancer diagnostics. Founded in 2012 and based in Kirkland, United States, the company was acquired by Agilent Technologies.
Get Freenome's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Freenome? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Freenome in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access